ADC Therapeutics S.A.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ameet Mallik
- Full Time Employees
- 191
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Biopole Epalinges VD Switzerland 1066
- IPO Date
- May 18, 2020
- CIK
- 0001771910
- Website
- adctherapeutics.com
- Similar Companies
- Business
- ADC Therapeutics SA (ADCT) develops and commercializes antibody drug conjugates (ADCs) for the treatment of hematologic malignancies and solid tumors. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC approved by the U.S. FDA, the European Commission and China's National Medical Products Administration for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior lines of systemic therapy; it advances ZYNLONTA expansions into earlier lines of DLBCL and indolent lymphomas such as follicular lymphoma and marginal zone lymphoma through the LOTIS-5 Phase 3 confirmatory trial, LOTIS-7 Phase 1b trial in combination with glofitamab, and investigator-initiated trials. Its early-stage pipeline features ADCT-241, an exatecan-based PSMA-targeting ADC in IND-enabling studies for prostate cancer, leveraging proprietary pyrrolobenzodiazepine (PBD) technology and novel hydrophilic linkers. Founded in 2011 and headquartered in Epalinges, Switzerland, ADC Therapeutics operates primarily in the U.S. and Europe with maximum revenue from the United States. In June 2025, the company completed a $100 million private placement financing of common shares and pre-funded warrants to extend its cash runway into 2028 and support ZYNLONTA catalysts alongside PSMA program advancement while discontinuing other preclinical solid tumor efforts; it recently granted inducement equity awards to new employees under its plan.
Company News
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics Q2 Earnings Call Highlights
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursday's Pre-Market Session (CORRECTED)
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcript
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma